POLISCOPE
Back to feed
NewsSouth Florida TimesOctober 27, 2026Miami-Dade County

Analysis links SGLT2 inhibitor diabetes and kidney drugs to longer survival in adults over 80

Photo: South Florida Times

A new analysis of electronic health records for adults aged 80 and older with chronic kidney disease links SGLT2 inhibitors to a lower risk of death and major kidney events, alongside increased risks for certain cardiac events and acute kidney injury. The findings were presented at ASN Kidney Week 2026 and are based on observational data rather than a completed peer-reviewed study.

Read the full story at South Florida Times

Why It Matters

Older adults and their clinicians navigating treatment decisions gain new real-world safety and efficacy data, though the observational findings carry mixed risks that complicate individual care choices.

Key Facts

  • Researchers analyzed electronic health records for 10,076 adults aged 80 or older with chronic kidney disease.
  • Starting SGLT2 inhibitors was associated with an 18% lower risk of death from any cause over a two-year follow-up.
  • Treatment was linked to a 22% lower risk of major adverse kidney events.
  • The analysis found higher risks of specific cardiac events, including heart attacks and acute heart failure, as well as acute kidney injury among those starting treatment.
  • There was no statistically significant reduction in major cardiovascular events overall.
  • People aged 80 and older are frequently underrepresented in large randomized drug trials.
  • The findings were presented at ASN Kidney Week 2026 as conference research awaiting further peer-reviewed scrutiny.

Who's Mentioned